(Q53509809)

15 May 2018

title

Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. (English)

1 reference

15 May 2018

7

Eric P Krenning

1 reference

15 May 2018

author name string

Edgar J Rolleman

1

1 reference

15 May 2018

Flavio Forrer

2

1 reference

15 May 2018

Bert Bernard

3

1 reference

15 May 2018

Magda Bijster

4

1 reference

15 May 2018

Marcel Vermeij

5

1 reference

15 May 2018

Roelf Valkema

6

1 reference

15 May 2018

Marion de Jong

8

1 reference

15 May 2018

publication date

5 December 2006

1 reference

15 May 2018

number of pages

9

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

15 May 2018

volume

34

1 reference

15 May 2018

issue

5

1 reference

15 May 2018

page(s)

763-771

1 reference

15 May 2018

Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-006-0291-3

Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues

21 January 2018

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

1 reference

12 December 2020

Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats

1 reference

12 December 2020

Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity

1 reference

12 December 2020

Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model

1 reference

12 December 2020

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

12 December 2020

Improved tolerability of amifostine with rapid infusion and optimal patient preparation

1 reference

12 December 2020

Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721

1 reference

12 December 2020

An anaphylactoid reaction from amifostine

1 reference

12 December 2020

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

1 reference

12 December 2020

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

12 December 2020

Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care

1 reference

12 December 2020

Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.

1 reference

12 December 2020

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.

1 reference

12 December 2020

Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals.

1 reference

12 December 2020

Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis

1 reference

12 December 2020

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.

1 reference

12 December 2020

Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome

1 reference

12 December 2020

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

1 reference

12 December 2020

Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins.

1 reference

12 December 2020

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

1 reference

12 December 2020

Radiation nephropathy

1 reference

12 December 2020

Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.

1 reference

12 December 2020

Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy

1 reference

12 December 2020

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

1 reference

12 December 2020

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

10.1007/S00259-006-0291-3

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018